This inventor holds 5 USPTO granted patents and 1 published patent application, plus 2 CIPO patents and 3 EPO patents. Top assignee: Oncotherapy Science, Incorporated. Active years: 2015-2017.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2015-2017
Title: Gaku Nakayama: Innovator in Cancer Immunotherapy
Introduction
Gaku Nakayama is a prominent inventor based in Kanagawa, Japan. He has made significant contributions to the field of cancer immunotherapy through his innovative research and development of peptides and vaccines. With a total of 5 patents, Nakayama's work is paving the way for new treatment options in oncology.
Latest Patents
One of Nakayama's latest patents focuses on TOPK peptides and vaccines. This invention provides isolated epitope peptides derived from TOPK, which have the ability to induce cytotoxic T lymphocytes (CTLs). These peptides are particularly suitable for use in cancer immunotherapy, serving as potential cancer vaccines. The invention encompasses both peptides that include a TOPK-derived amino acid sequence and modified versions, ensuring CTL inducibility. Additionally, the patent includes polynucleotides encoding these peptides and pharmaceutical compositions that incorporate them, highlighting their utility in treating and preventing various cancers.
Another significant patent by Nakayama involves TOMM34 peptides and vaccines. This invention provides isolated peptides or fragments derived from specific amino acid sequences that bind to HLA antigens and induce CTLs. Similar to his previous work, these peptides can be modified through substitution, deletion, or addition of amino acids. The pharmaceutical compositions developed from these peptides are aimed at treating cancer, showcasing Nakayama's commitment to advancing cancer therapies.
Career Highlights
Gaku Nakayama is currently associated with Oncotherapy Science, Incorporated, where he continues to innovate in the field of cancer treatment. His work is characterized by a strong focus on developing effective immunotherapeutic strategies that can significantly impact patient outcomes.
Collaborations
Nakayama collaborates with notable colleagues in the field, including Yusuke Nakamura and Takuya Tsunoda. Their combined expertise enhances the research and development efforts at Oncotherapy Science, Incorporated.
Conclusion
Gaku Nakayama's contributions to cancer immunotherapy through his innovative patents and collaborations are noteworthy. His work not only advances scientific understanding but also holds promise for improving cancer treatment options in the future.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile